James Huang - 24 Aug 2022 Form 4 Insider Report for CASI Pharmaceuticals, Inc.

Role: Director
Signature: /s/ James Huang
Issuer symbol: N/A
Transactions as of: 24 Aug 2022
Net transactions value: +$166,930
Form type: 4
Filing time: 26 Aug 2022, 20:48:27 UTC
Previous filing: 23 Aug 2022
Next filing: 02 Sep 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CASI	Common Stock	Purchase	$18,751	+5,000	+2.1%	$3.75^*	239,221	24 Aug 2022	See Footnote	F1
transaction	CASI	Common Stock	Purchase	$148,179	+39,527	+17%	$3.75^*	278,748	26 Aug 2022	See footnote	F1, F2
holding	CASI	Common Stock						191	24 Aug 2022	Direct

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.
F2	The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Content

Represents securities held by Panacea Opportunity Fund I, L.P., over which the reporting person may be deemed to indirectly share beneficial ownership. The reporting person disclaims such beneficial ownership except to the extent of his pecuniary interest therein, if any.

The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $3.70 to $3.75. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.